Holen Sie sich die Stockscreener-App
14.99
8.23%
1.14
Schlusskurs vom Vortag:
$13.85
Offen:
$14.12
24-Stunden-Volumen:
2.69M
Relative Volume:
1.00
Marktkapitalisierung:
$11.16B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-921.61M
KGV:
-12.07
EPS:
-1.2418
Netto-Cashflow:
$-274.60M
1W Leistung:
+3.52%
1M Leistung:
-19.67%
6M Leistung:
-47.44%
1J Leistung:
-27.48%
1-Tages-Spanne:
$14.04
$15.11
1-Wochen-Bereich:
$13.83
$15.11
52-Wochen-Spanne:
$13.83
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
14.99 | 10.31B | 220.00K | -921.61M | -274.60M | -1.2418 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Underweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
FDA Accepts Summit Therapeutics’ (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data - Yahoo Finance
Summit Therapeutics stock hits 52-week low at 14.01 USD By Investing.com - Investing.com Canada
FDA Accepts Summit Therapeutics' (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data - Finviz
Merger Talk: Is Summit Therapeutics Inc impacted by rising rates2025 Buyback Activity & Fast Moving Stock Trade Plans - baoquankhu1.vn
Summit Therapeutics (NASDAQ:SMMT) Reaches New 12-Month LowShould You Sell? - MarketBeat
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer - MSN
Summit Therapeutics (NASDAQ:SMMT) Research-Driven Model In Nasdaq Index - Kalkine Media
Summit Therapeutics (SMMT) Stock Analysis: A Potential 128% Upside In Biotech - DirectorsTalk Interviews
HC Wainwright Reaffirms Buy Rating for Summit Therapeutics (NASDAQ:SMMT) - MarketBeat
H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock - Investing.com
Summit Therapeutics (SMMT) Analyst Ratings Reaffirmed at Buy | S - GuruFocus
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 30, 2026 - BioSpace
Encouraging guidance on clinical program makes Summit Therapeutics (SMMT) look attractive - MSN
2 Stocks That Could Soar This Year - The Globe and Mail
Summit spikes as lead asset undergoes FDA review - MSN
Yong Rong HK Asset Management Ltd Invests $2.07 Million in Summit Therapeutics PLC $SMMT - MarketBeat
FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug - Finviz
Summit Therapeutics (SMMT) Analyst Rating Update: January 30, 20 - GuruFocus
Summit Therapeutics' (SMMT) Market Outperform Rating Reiterated at Citizens Jmp - MarketBeat
Summit Therapeutics: PDUFA Coming, But Is It Good Enough? (Rating Upgrade) (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics stock gets FDA acceptance for ivonescimab BLA - Investing.com
Summit Therapeutics stock gets FDA acceptance for ivonescimab BLA By Investing.com - Investing.com Canada
US regulator accepts Summit filing for ivonescimab combo - The Pharma Letter
Summit Therapeutics (SMMT) Valuation Check After Recent Share Price Pullback And Conflicting Model Signals - Yahoo Finance
FDA Accepts Summit Therapeutics' BLA for Ivonescimab - intellectia.ai
FDA Accepts Summit's Lung Cancer Drug Application, Review Underway - Benzinga
Aug Gainers: Is Summit Therapeutics Inc impacted by rising rates2025 Risk Factors & Growth Focused Stock Reports - baoquankhu1.vn
Summit Therapeutics (SMMT) Advances with FDA Filing for Cancer T - GuruFocus
Summit Therapeutics Says US FDA Accepts BLA for Ivonescimab - marketscreener.com
Summit Therapeutics (SMMT) Gains After FDA Accepts Key Cancer Dr - GuruFocus
Summit Therapeutics’ Ivonescimab BLA Accepted by FDA - TipRanks
Summit spikes as lead asset gets FDA review (SMMT:NASDAQ) - Seeking Alpha
Summit Therapeutics stock rises after FDA accepts BLA for lung cancer drug - Investing.com Nigeria
Summit Therapeutics Inc FDA Accepts Ivonescimab BLA for NSCLC Treatment - TradingView
FDA accepts Summit Therapeutics BLA for lung cancer drug ivonescimab - StreetInsider
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy - Chartmill
Summit Therapeutics (NASDAQ:SMMT) Sets New 12-Month LowHere's What Happened - MarketBeat
Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive - Finviz
Exelixis and Summit Therapeutics: Future Prospects - Intellectia AI
Aug Retail: Can Summit Therapeutics Inc be the next market leaderPortfolio Risk Summary & Fast Moving Market Watchlists - baoquankhu1.vn
Trading the Move, Not the Narrative: (SMMT) Edition - Stock Traders Daily
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring a 100.75% Potential Upside in Biotech Investment - DirectorsTalk Interviews
Breakout Move: What is Summit Therapeutics Inc.’s TAM (Total Addressable Market)Options Play & Long-Term Safe Investment Ideas - mfd.ru
Will Ivonescimab’s FDA Filing and GSK Combo Trial Redefine Summit Therapeutics’ (SMMT) Core Narrative? - Sahm
Summit Therapeutics (NASDAQ:SMMT) Share Price Passes Above 50 Day Moving AverageHere's What Happened - MarketBeat
Trip.com, Regencell Bioscience, And Atlassian Are Among Top 10 Large Cap Losers Last Week (Jan. 12-Jan. 16): Are the Others in Your Portfolio? - Benzinga
Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation - MSN
(SMMT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Is Summit Therapeutics (SMMT) Building a Durable Oncology Combination Platform With Ivonescimab’s Expanding Reach? - Sahm
Buyout Rumor: Will Summit Therapeutics Inc outperform the market in YEAR2025 Major Catalysts & Long-Term Growth Stock Strategies - baoquankhu1.vn
Summit Therapeutics Advances Ivonescimab Into Key Phase 3 Test in Metastatic Colorectal Cancer - TipRanks
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
1.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):